BORUI Pharmaceuticals: plans to increase investment in Laiticon by 30 million yuan, focusing on the research and development of innovative antibody drugs.

Buray Pharmaceuticals announced that the company plans to increase its investment in Lotekang Biopharmaceutical Co., Ltd. by 30 million yuan, of which 46.119 million yuan will be subscribed as new registered capital for Lotekang, and the remaining amount will be included in the capital surplus of the target company. Before this capital increase, the company held 11.51312% equity in the target company, and after the increase, it will hold 16.52181% equity. The target company focuses on the research and development of innovative antibody drugs, with multiple drugs in clinical trials or preclinical research stages. The research and development of the existing product pipeline and other candidate new drugs involve uncertainties, and the progress of clinical trials of drugs under research or the results of clinical trials may not meet expectations.